A claims analysis from ALZpath finds growing testing volume and average payments for phosphorylated tau testing under traditional Medicare.
Utilization of phosphorylated tau (p-tau) testing for Alzheimer’s disease is growing under traditional Medicare Part B, and most claims are being paid, according to a real-world analysis announced by ALZpath. The analysis covered claims from January 2025 through April 2026 and found increases in both testing volume and average payments. Nearly 78% of claims received payment.
The findings will be presented at the Clinical Trials on Alzheimer’s Disease conference in Boston on Thursday, Nov 19.
“These findings provide an important real-world view of how blood-based Alzheimer’s testing is being used and reimbursed under Medicare,” says Mike Banville, CEO of ALZpath, in a release. “While the data show that reimbursement is already occurring in a substantial proportion of cases, establishing clear and consistent coverage policies will be critical as these tests become more widely used in clinical practice.”
Study Design
The study used the LumaClaims database to analyze claims submitted under CPT code 84393, which covers p-tau testing in plasma and cerebrospinal fluid. Based on a review of other codes associated with CPT 84393, only a small fraction of the claims are likely to represent cerebrospinal fluid testing, according to the company.
A subset analysis of 42,380 claims that included an associated venipuncture CPT code found reimbursement rates and amounts similar to those in the full dataset.
The majority of claims were associated with laboratory-developed tests. The authors note that further research is needed to assess utilization and reimbursement as FDA-cleared in vitro diagnostic tests become more widely available.
“Real-world claims data offer a baseline for understanding the adoption and reimbursement of emerging diagnostic technologies beyond controlled research settings,” says Soeren Mattke, director of the USC Brain Health Observatory at the University of Southern California and a co-author of the study, in a release. “These findings provide an important initial benchmark for tracking pTau testing utilization and coverage under traditional Medicare as new testing options become available.”
ALZpath’s proprietary pTau217 antibody is used in many blood-based Alzheimer’s tests. The company has licensed the antibody to Abbott, Beckman Coulter, Roche, Siemens Healthineers, Alamar Biosciences, Bio-Techne, and Quanterix.
ID 272666856 © Luchschen | Dreamstime.com